日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

同源重组缺陷和半合子状态是乳腺癌耐药性的驱动因素

Safonov, Anton; Lee, Minna; Brown, David N; Boscolo Bielo, Luca; Mehine, Miika; Bandlamudi, Chaitanya; O'Leary, Ben; Shao, Hong; Vicente, Laia; Muldoon, Daniel; Zhu, Allen; Ros, Susana; Marra, Antonio; Selenica, Pier; Bieche, Ivan; Wubbenhorst, Bradley; Ferraro, Emanuela; Courtois, Laura; El Botty, Rania; Ahmed, Mehnaj; Moiso, Enrico; An, Julia Ah-Reum; Donoghue, Mark T A; Will, Marie; Pareja, Fresia; Nizialek, Emily; Lukashchuk, Natalia; Sofianopoulou, Eleni; Liu, Yuan; Huang, Xin; Chappey, Colombe; Staniszewska, Anna D; Ross, Dara; Mandelker, Diana; Ladanyi, Marc; Schultz, Nikolaus; Berger, Michael F; Scaltriti, Maurizio; Reis-Filho, Jorge S; Li, Bob T; Offit, Kenneth; Norton, Larry; Shen, Ronglai; Maxwell, Kara N; Couch, Fergus; Domchek, Susan M; Marangoni, Elisabetta; Shah, Sohrab; Albertella, Mark R; Serra, Violeta; Weigelt, Britta; Solit, David B; Nathanson, Katherine L; Robson, Mark E; Turner, Nicholas C; Chandarlapaty, Sarat; Razavi, Pedram

Tracking response to neoadjuvant systemic therapy through circulating tumor DNA analysis in breast cancer

通过循环肿瘤DNA分析追踪乳腺癌新辅助全身治疗的反应

Marra, Antonio; Kim, Sarah H; Pareja, Fresia; Basili, Thais; Solit, David B; Chandarlapaty, Sarat; Plitas, George; Reis-Filho, Jorge S; Weigelt, Britta; King, Tari A; Brown, David N

Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research

远程医疗与面对面知情同意在临床癌症研究中的质量比较

Sternschuss, Michal; Lattanzi, Michael; Vertosick, Emily; Austria, Mia; Martin, Sené; Regazzi, Ashley; Buckely, Michael T; Lengfellner, Joseph; Riely, Gregory J; Solit, David B; Rosenberg, Jonathan E; Iyer, Gopa; Stetson, Peter D; Morris, Michael J; Vickers, Andrew J; Funt, Samuel A

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

奈拉替尼治疗ERBB2突变型肺腺癌的疗效:两项国际II期研究的结果

Li, Bob T; Gandhi, Leena; Ravichandran, Vignesh; Besse, Benjamin; Mazières, Julien; Shapiro, Geoffrey I; Boni, Valentina; Waqar, Saiama N; Park, Haeseong; Quinn, David I; Martinez, Alejandro; Stemmer, Salomon M; Cortot, Alexis B; Barlesi, Fabrice; Quoix, Elisabeth; Burkard, Mark E; Selcuklu, S Duygu; Hunt, Casey; Donoghue, Mark T A; Kris, Mark G; Bebchuk, Judith; Eli, Lisa D; McCulloch, Leanne; Solit, David B; Jänne, Pasi A

Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets

对早期膀胱癌进行临床和基因组分析,可识别关键改变和治疗靶点。

Magnani, Christopher J; D'Andrea, Vincent D; Barros, Guilherme Garcia; Qian, Zhiyu; Ernandez, John; Yim, Kendrick; Kibel, Adam S; Chang, Steven L; Mossanen, Matthew; Preston, Mark A; Feldman, Adam S; Bochner, Bernard H; Solit, David B; Pietzak, Eugene J; Mouw, Kent W; Carvalho, Filipe L F; Clinton, Timothy N

Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer.

对肿瘤抑制基因双等位基因失活的泛癌分析表明,KEAP1 合子性是肺癌的预测性生物标志物

Zucker Mark, Perry Maria A, Gould Samuel I, Elkrief Arielle, Safonov Anton, Thummalapalli Rohit, Mehine Miika, Chakravarty Debyani, Brannon A Rose, Ladanyi Marc, Razavi Pedram, Donoghue Mark T A, Murciano-Goroff Yonina R, Grigoriadis Kristiana, McGranahan Nicholas, Jamal-Hanjani Mariam, Swanton Charles, Chen Yuan, Shen Ronglai, Chandarlapaty Sarat, Solit David B, Schultz Nikolaus, Berger Michael F, Chang Jason, Schoenfeld Adam J, Sánchez-Rivera Francisco J, Reznik Ed, Bandlamudi Chaitanya

Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies

基于遗传祖先的差异对基于生物标志物的精准肿瘤治疗资格的影响

Arora, Kanika; Suehnholz, Sarah P; Zhang, Hongxin; Ostrovnaya, Irina; Kundra, Ritika; Nandakumar, Subhiksha; Nissan, Moriah H; Brannon, A Rose; Bandlamudi, Chaitanya; Ladanyi, Marc; Drilon, Alexander; Brown, Carol L; Solit, David B; Schultz, Nikolaus; Berger, Michael F; Chakravarty, Debyani

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

尿路上皮癌对HER2靶向抗体药物偶联物敏感性的决定因素

Chen, Ziyu; Tang, Xinran; Eichholz, Jordan E; Mcpherson, Andrew; Thomas, Jasmine; Nagar, Karan; Rustgi, Naryan; Christin, John R; Kuo, Fengshen; Gao, Sizhi; Jiang, Hui; Luo, Jiaqian; Ostrovnaya, Irina; Basar, Merve; Pietzak, Eugene; Coleman, Jonathan A; Berger, Michael F; de Stanchina, Elisa; Shah, Sohrab P; Mohibullah, Neeman; Aggen, David H; Rosenberg, Jonathan E; Chandarlapaty, Sarat; Shen, Michael M; Al-Ahmadie, Hikmat; Iyer, Gopa; Kim, Kwanghee; Solit, David B

Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.

调节 PPARγ 通路可上调 NECTIN4,并增强嵌合抗原受体 (CAR) T 细胞疗法在膀胱癌中的疗效

Chang Kevin, Delavan Henry M, Yip Elizabeth, Kasap Corynn, Zhu Jun, Lodha Roshan, Liao Sheng-You, Berman Sarah C, Carretero-Gonzalez Alberto, Basar Merve, Gokturk Ozcan Gamze, Teo Min Yuen, Solit David B, Rosenberg Jonathan E, Al-Ahmadie Hikmat, Ding Cornelia C K, Chan Emily, Steri Veronica, Porten Sima P, Koshkin Vadim S, Friedlander Terence W, Feng Felix Y, Lee John K, Wiita Arun P, Chu Carissa E, Chou Jonathan

Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer

生殖系DNA损伤修复变异与高危或转移性前列腺癌患者的预后

Stopsack, Konrad H; Vijai, Joseph; Conry, Michael; Berchuck, Jacob E; Kemel, Yelena; Vasselman, Samantha E; Freeman, Dory A; Lee, Gwo-Shu M; Mandelker, Diana; Solit, David B; Morris, Michael J; Penney, Kathryn L; Abida, Wassim; Offit, Kenneth; Mucci, Lorelei A; Kantoff, Philip W; Pomerantz, Mark M